FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy

On November 21, 2016, the U.S. Food and Drug Administration granted regular approval to daratumumab in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. Approval was base...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhatnagar, Vishal, Gormley, Nicole J., Luo, Lola, Shen, Yuan Li, Sridhara, Rajeshwari, Subramaniam, Sriram, Shen, Guoxiang, Ma, Lian, Shord, Stacy, Goldberg, Kirsten B., Farrell, Ann T., McKee, Amy E., Pazdur, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Regulatory Issues: FDA
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679834/
https://www.ncbi.nlm.nih.gov/pubmed/28904172
http://dx.doi.org/10.1634/theoncologist.2017-0229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679834/
https://www.ncbi.nlm.nih.gov/pubmed/28904172
http://dx.doi.org/10.1634/theoncologist.2017-0229

Ejemplares similares